Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 3, 2006, Pages 536-545

  Siquier, B ^a   Sanchez Alvarez J ^b   Garcia Mendez E ^c   Sabria M ^d   Santos, J ^e   Pallares R ^f   Twynholm, M ^g   Dal Ré, Rafael ^c   Adrover, A ^a   Vidal, J ^a   Aguado, J M ^h   Aguero R ⁱ   Aguilar, L ^c   Garcia Rey C ^c   Arjona, R ^j   Bardagi S ^k   Barrufet, P ^k   Blanquer, R ^l   Bravo, C ^m   Carrasco, I ⁿ   Condes F ^o   Custardoy, J ^p   De Teresa, L ^q   Mirete, C ^q   De la Torre, J ^r,s   Duran, J ^t   Falguera, M ^u   Garau, J ^v   Gil Aguado, A ^w   Gomez J ^x   Gorgolas M ^y   Grau, I ^f   Hernandez J ^z   Molinos, L ^aa   Pachon J ^ab   Palacios, R ^e   Picazo, J ^ac   Perez S ^ad   Reynaga, E ^ae   Rivas, M ^af   Suarez M J ^af   Sanz M J ^ag   Wilhelmi, I ^ag   Sesma, J ^b   Sobradillo, V ^ah   Viejo, J L ^ai   Zubillaga, G ^aj   Hodge, Rachel ^g   Kalia, Veena ^g   more..

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Universidad Pública de Navarra   (Spain)

^c GLAXOSMITHKLINE   (Spain)

^d Infectious Diseases Unit   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g GLAXOSMITHKLINE   (United Kingdom)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^j HOSPITAL SIERRALLANA   (Spain)

^k Hospital of Mataro   (Spain)

^l HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ Hospital Municipal   (Spain)

^o QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^p HOSPITAL VEGA BAJA   (Spain)

^q Hospital Veterinario San Vicente del Raspeig   (Spain)

^r HOSPITAL COSTA DEL SOL   (Spain)

^s HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^t HOSPITAL TXAGORRITXU   (Spain)

^u HOSPITAL ARNAU DE VILANOVA   (Spain)

^v HOSPITAL MÚTUA DE TERRASSA   (Spain)

^w HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^x HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^y Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^z HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^aa HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^ab HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^ac HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^ad HOSPITAL DE JEREZ   (Spain)

^ae HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^af HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^ag HOSPITAL SEVERO OCHOA   (Spain)

^ah HOSPITAL DE CRUCES   (Spain)

^ai HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^aj HOSPITAL DONOSTIA   (Spain)

more..

Author keywords

lactams; Anti infective development; Antimicrobial therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PENICILLIN G;

ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD SAMPLING; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYSTALLURIA; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PENICILLIN RESISTANCE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SPAIN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; URINALYSIS; URINARY EXCRETION;

ADULT; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 32644453940     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki480     Document Type: Article

References (32)

1. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
2. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-41.
3. Smith RD, Coast J. Antimicrobial resistance: A global response. Bull World Health Organ 2002; 80: 126-33.
4. Baquero F, Garcia-Rodriguez JA, Garcia de Lomas J et al. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother 1999; 43: 357-9.
5. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45: 3334-40.
6. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C et al. Geographical and ecological analysis of resistance, coresistance and coupled-resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72.
7. Jacobs MR. Streptococcus pneumoniae: Epidemiology and patterns of resistance. Am J Med 2004; 117 Suppl 3A: 3S-15.
8. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
9. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
10. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-9.
11. File T. Appropriate use of antimicrobials for drug resistant pneumonia: focusonthe significance of β-lactam resistant S. pneumoniae. Clin Infect Dis 2002; 34 (Suppl.1): S17-26.
12. Doit C, Loukil C, Fitoussi F et al. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob Agents Chemother 1999; 43: 1480-3.
13. Perez-Trallero E, Marimon JM, Gonzalez A et al. Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2003; 47: 3637-9.
14. Fenoll A, Martin Bourgon C, Munoz R et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991; 13: 56-60.
15. Kaye CM, Allen A, Perry S et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001; 23: 578-84.
16. White AR, Kaye C, Poupard J et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 (Suppl 1): I3-20.
17. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th edn. Approved Standard. NCCLS document M7-A5. Wayne, PA:NCCLS 2000.
19. National Committe for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard. NCCLS document M2-A7. Wayne, PA:NCCLS 2000.
20. National Committe for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, 11th Informational Supplement. Approved Standard. NCCLS document M100-S11. Wayne, PA: NCCLS 2001.
21. Ball P, Baquero F, Cars O et al. Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
22. Dagan R, Leibovitz E, Greenberg D et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17: 776-82.
23. Dagan R, Klugman KP, Craig WA et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-40.
24. Garau J. Performance in practice: Bacteriological efficacy in patients with drug-resistant S. pneumoniae. Clin Microbiol Infect 2004; 10 Suppl 2: 28-35.
25. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
26. Garau J, Twynholm M, Garcia-Mendez E et al. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003; 52: 826-36.
27. Petitpretz P, Chidiac C, Soriano F et al. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 2002; 20: 119-29.
28. File TM, Jr, Lode H, Kurz H et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004; 48: 3323-31.
29. Azoulay-Dupuis E, Moine P. Mouse pneumococcal pneumonia models. In: Zak O, Sande MA. Eds, Handbook of Animal Models of Infection. London: Academic Press, 1999; pp. 481-93.
30. Oteo J, Lazaro E, de Abajo FJ et al. Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): Decreasing penicillin resistance in children's isolates. J Clin Microbiol 2004; 42: 5571-7.
31. Fenoll A, Asensio G, Jado I et al. Antimicrobial susceptibility and pneumococcal serotypes. J Antimicrob Chemother 2002; 50 Suppl S2: 13-9.
32. Mills GD, Oehley MR, Arrol B. Effectiveness of β-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: Meta-analysis. BMJ 2005; 330: 456.